GPA
IBB icon

Garrison Point Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Garrison Point Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.89M Sell
9,944
-159
-2% -$27.3K 0.77% 33
2026
Q1 		$1.71M Sell
10,103
-100
-1% -$17.1K 0.78% 34
2025
Q4 		$1.72M Sell
10,203
-185
-2% -$30K 0.76% 33
2025
Q3 		$1.5M Sell
10,388
-181
-2% -$24.7K 0.63% 39
2025
Q2 		$1.34M Sell
10,569
-470
-4% -$57.7K 0.61% 46
2025
Q1 		$1.41M Buy
11,039
+621
+6% +$84.2K 0.68% 41
2024
Q4 		$1.38M Sell
10,418
-92
-0.9% -$12.9K 0.65% 42
2024
Q3 		$1.53M Buy
10,510
+68
+0.7% +$9.84K 0.95% 32
2024
Q2 		$1.43M Buy
10,442
+158
+2% +$21.1K 0.95% 29
2024
Q1 		$1.41M Buy
10,284
+217
+2% +$29.6K 0.91% 30
2023
Q4 		$1.37M Sell
10,067
-35
-0.3% -$4.27K 0.96% 31
2023
Q3 		$1.24M Sell
10,102
-82
-0.8% -$10.4K 0.96% 30
2023
Q2 		$1.29M Sell
10,184
-50
-0.5% -$6.5K 0.93% 31
2023
Q1 		$1.32M Buy
10,234
+6
+0.1% +$785 0.99% 27
2022
Q4 		$1.34M Hold
10,228
– – 1.1% 27
2022
Q3 		$1.2M Buy
10,228
+30
+0.3% +$3.73K 1.07% 29
2022
Q2 		$1.2M Buy
10,198
+48
+0.5% +$5.7K 1% 34
2022
Q1 		$1.32M Buy
10,150
+217
+2% +$28.3K 0.93% 32
2021
Q4 		$1.52M Buy
9,933
+257
+3% +$39.8K 1.01% 28
2021
Q3 		$1.56M Sell
9,676
-70
-0.7% -$11.8K 1.14% 26
2021
Q2 		$1.59M Sell
9,746
-10
-0.1% -$1.54K 1.15% 26
2021
Q1 		$1.47M Sell
9,756
-20
-0.2% -$3.18K 1.14% 27
2020
Q4 		$1.48M Hold
9,776
– – 1.19% 24
2020
Q3 		$1.32M Sell
9,776
-10
-0.1% -$1.36K 1.2% 25
2020
Q2 		$1.34M Sell
9,786
-515
-5% -$65.7K 1.32% 23
2020
Q1 		$1.11M Sell
10,301
-315
-3% -$36.3K 1.36% 27
2019
Q4 		$1.28M Sell
10,616
-60
-0.6% -$6.69K 1.17% 32
2019
Q3 		$1.06M Buy
10,676
+200
+2% +$20.9K 1.05% 34
2019
Q2 		$1.14M Buy
10,476
+345
+3% +$36.7K 1.15% 32
2019
Q1 		$1.13M Buy
10,131
+435
+4% +$47.7K 1.18% 30
2018
Q4 		$935K Buy
+9,696
New +$1.03M 1.15% 31

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Garrison Point Advisors's IBB Position: Q2 2026 in Review

Garrison Point Advisors reduced its iShares Biotechnology ETF (IBB) stake by 1.6% in Q2 2026, selling an estimated $27.3K and leaving 9,944 shares worth $1.89M. The position accounts for 0.77% of the portfolio, ranked #33.

Garrison Point Advisors first reported a position in IBB in Q4 2018 and has held it in 31 quarters since. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Garrison Point Advisors held 9,944 shares of iShares Biotechnology ETF worth $1.89M as of Q2 2026.
  • Garrison Point Advisors sold 159 iShares Biotechnology ETF shares in Q2 2026, an estimated $27.3K.
  • iShares Biotechnology ETF made up 0.77% of Garrison Point Advisors's portfolio in Q2 2026, its #33 holding.
  • Garrison Point Advisors first reported a position in iShares Biotechnology ETF in Q4 2018 and has held it in 31 quarters since.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Garrison Point Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.